Low-intensity extracorporeal shock wave therapy is a safe treatment for men with erectile dysfunction and might work to improve, or even cure, ED in some patients. But there remain important ...

First-line nivolumab (Opdivo) plus ipilimumab (Yervoy) continued to show improved survival and durable response benefits vs sunitinib (Sutent) in patients with previously untreated advanced renal cell ...

Results of subgroup analyses of the phase 3 CREST trial (NCT04165317) evaluating sasanlimab plus BCG compared with BCG alone in patients with high-risk non–muscle invasive bladder cancer (NMIBC) found ...

In this interview, Mark C. Markowski, MD, PhD, discusses bipolar androgen therapy (BAT), including its advantages and disadvantages, trials that have evaluated the treatment, and what some next steps ...

We identify a statistically higher odds of urethral stricture, genital numbness, and saddle sores (OR: 9.8, p<.001) in cyclists compared to swimmers/runners.Several other large studies corroborate ...

Specifically, the bill cuts funding for CDMRP from $1.509 billion in FY2024 to $650 million in FY2025. Prostate and kidney cancer research is currently funded at $110 million and $50 million, ...

Key Takeaways. Prostate cancer is the most common urologic cancer, with PSA screening reducing mortality by up to 20% in men aged 55–69. Bladder cancer incidence is stable, with early detection ...

In this interview, Patrick Soon-Shiong, MD, shares key updates in the development of nogapendekin alfa inbakicept-pmln (Anktiva), which was approved by the FDA in April 2024 for patients with ...

MD, professor of urology and chief of andrology at Tulane University School of Medicine, in New Orleans, Louisiana. “About 20 years ago, when I gave a course at the American Urological Association ...

In this interview, Mohit Khera, MD, MBA, MPH, shares insights on the use of testosterone replacement therapy in men with prostate cancer, touching on current evidence and also stressing the importance ...

From 1999 to 2016, testosterone levels have declined in adolescent and young adult men (AYA), according to results presented at the 2020 American Urological Association Virtual Experience 1. “Overall ...

The ODAC meeting was called to discuss the submitted new drug application (NDA) for UGN-102, which the agency previously accepted in October 2024, issuing a Prescription Drug User Fee Act (PDUFA) ...